 The Brazilian Health Regulatory Agency has approved PTC Therapeutics Incs NASDAQ: PTCT Waylivra volanesorsen as the first treatment for familial chylomicronemia syndrome FCS. The approval is based on the Phase 3 APPROACH study results and the APPROACH Open-Label Extension study and is supported by results from the Phase 3 COMPASS study. 